Temozolomide followed by combined immunotherapy with GM-CSF, low-dose IL2 and IFN alpha in patients with metastatic melanoma. [electronic resource]
Producer: 20030325Description: 175-80 p. digitalISSN:- 0007-0920
- Adult
- Aged
- Antineoplastic Agents, Alkylating -- adverse effects
- Dacarbazine -- adverse effects
- Disease-Free Survival
- Drug Therapy, Combination
- Eye Neoplasms -- drug therapy
- Female
- Granulocyte-Macrophage Colony-Stimulating Factor -- adverse effects
- Humans
- Immunotherapy
- Interferon alpha-2
- Interferon-alpha -- adverse effects
- Interleukin-2 -- adverse effects
- Lymphocyte Activation -- drug effects
- Male
- Maximum Tolerated Dose
- Melanoma -- drug therapy
- Middle Aged
- Neoplasm Staging
- Recombinant Proteins
- Skin Neoplasms -- drug therapy
- T-Lymphocyte Subsets -- metabolism
- Temozolomide
- Treatment Outcome
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.